We want to share that Biocytogen will be attending Catalyzing Innovation in Connecticut: Top Visionaries Discuss Innovation Opportunities in the State presented by BioCT, on June 26th 2025 in Stamford, Connecticut. Come join us to network with Connecticut's leading innovators, explore groundbreaking ideas, and discuss the future of biotechnology in the state. Don't miss the chance to learn more about our newest models and antibody-related drug developments.
What is Catalyzing Innovation in Connecticut (BioCT)
Catalyzing Innovation in Connecticut: Top Visionaries Discuss Innovation Opportunities is an event presented by BioCT, the state's leading bioscience business group. This gathering aims to bring together top visionaries to discuss and explore innovation opportunities within Connecticut. The event serves as a platform for networking, collaboration, and exchanging ideas among professionals in the bioscience sector. Attendees can expect to engage with industry leaders, learn about the latest advancements, and explore potential partnerships to drive innovation in the state.
Event Overview
Date: June 26, 2025 5:00 PM - 7:00 PM
Venue: The Village, 4 Star Point Suite 101, Stamford, CT
Event Schedule
The event includes panel discussions and networking with the state’s top biotech professionals. For more details, please refer to Catalyzing Innovation in Connecticut.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to meeting you at the Catalyzing Innovation in Connecticut!
